Therapy News and Research

RSS

Mirada Medical and Moffitt Cancer Center enter joint development agreement

Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced today that they have signed an agreement with Moffitt Cancer Center, Tampa, FL, one of the USA's top centers for cancer treatment and oncology research.

28 Oct 2010

JMC Professor wins Karl Storz Lifetime Achievement Award in Endourology

Demetrius H. Bagley, M.D., the Nathan Lewis Hatfield Professor of Urology in the Department of Urology at Jefferson Medical College (JMC) of Thomas Jefferson University was recently honored as the 2010 recipient of the Karl Storz Lifetime Achievement Award in Endourology at the World Congress of Endourology. He is also a full Professor of Radiology.

28 Oct 2010

World's largest free-standing proton therapy center opens

Hampton University, along with the Honorable Gov. Bob McDonnell and hundreds of guests, celebrated the grand opening of the Hampton University Proton Therapy Institute (HUPTI), the world's largest free-standing proton center, on Thursday.

28 Oct 2010

KCI announces U.S. launch of Skin IQ MCM for pressure ulcers

Kinetic Concepts, Inc. announced today the U.S. launch of Skin IQ Microclimate Manager (Skin IQ MCM) through KCI's Therapeutic Support Systems business. Skin IQ MCM is a for-sale, powered coverlet offering clinicians one of the most effective and intuitive products available for the prevention and management of pressure ulcers.

28 Oct 2010

Calypso Medical initiates clinical study to evaluate tracking technology for lung tumors

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumors, today announced the initiation of the first clinical study to evaluate the use of the Calypso System for tracking lung cancer tumors during radiation delivery, including a new design of the Company's implantable Beacon transponder.

28 Oct 2010

New national campaign to drive awareness on DVT and PE prevention in women

As many as 600,000 people are affected by deep vein thrombosis (DVT) and pulmonary embolism (PE) every year, and more than half of those are never diagnosed. Some people experience swelling and varying levels of discomfort in the affected area, and some don't feel anything at all. But the symptoms of DVT can be similar to other conditions, like a pulled muscle, and because some people with DVT do not have any symptoms, there is often a delay in diagnosis. That's when DVT can be fatal.

28 Oct 2010

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

ChemoCentryx, Inc., today announced that it reported one-year results from the Company's PROTECT-1 Study (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN™ (CCX282-B) in patients with moderate-to-severe Crohn's disease. Traficet-EN, an orally bioavailable CCR9-specific chemokine receptor antagonist showed clinical efficacy in a 12-week Induction period, as well as a 36-week Maintenance period.

28 Oct 2010

EpiCept, FDA reach agreement on regulatory path forward for Ceplene

EpiCept Corporation today announced that it has reached an agreement on all outstanding issues with the U.S. Food and Drug Administration (FDA) on a regulatory path forward for Ceplene® (histamine dihydrochloride), the Company's lead product for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first complete remission. Ceplene® is approved in the European Union for this indication and is marketed there by Meda AB.

28 Oct 2010

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).

28 Oct 2010

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Boehringer Ingelheim Ltd. today announces that Health Canada has granted approval of PRADAX (dabigatran etexilate), an oral anticoagulant for the prevention of stroke and systemic embolism in adults with atrial fibrillation in whom anticoagulation is appropriate. PRADAX is the first innovative drug approved in Canada in more than two decades to reduce the risk of stroke in Canadians with atrial fibrillation.

28 Oct 2010

New findings suggest way to treat lung diseases

A new study of an exotic, infectious virus that has caused three recent outbreaks in the United States reveals clues to how the virus might damage lungs during infection. The findings also suggest possible new ways to treat lung diseases in humans.

28 Oct 2010

New intervention strategies help manage depression

In the 15 minutes a primary care doctor typically has with a patient, she's expected to diagnose the current ailment, help manage ongoing health issues and provide preventive care. In this setting, confronting all but the most obvious and immediate mental health needs of patients is an ongoing challenge.

27 Oct 2010

New type of radiation reduces GI side effects but does not improve survival rate in prostate cancer patients

A new British review of existing research suggests that while a newer type of radiation for the treatment of prostate cancer does not help patients live longer compared to an older type at least when similar doses are given it does appear to reduce gastrointestinal side effects.

27 Oct 2010

PSA test helps detect prostate cancer before it spreads

In addition to saving lives, a new study indicates routine prostate-specific antigen (PSA) testing improves quality of life by substantially reducing the risk that prostate cancer will spread to other parts of the body.

27 Oct 2010

Quebec recognizes value of ABILIFY for treating schizophrenia and related psychotic disorders

Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.

27 Oct 2010

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan Corporation, plc today reported its third quarter and first nine months 2010 financial results.

27 Oct 2010

New guideline for using ESAs drugs in cancer patients

An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.

27 Oct 2010

Reactivating three silenced molecules may provide new strategy to treat multiple myeloma

New research links three molecules to a critical tumor suppressor gene that is often turned off in multiple myeloma, a presently incurable cancer of the blood.

27 Oct 2010

IMRT reduces gastrointestinal complications in prostate cancer patients

Prostate cancer patients who receive intensity modulated radiation therapy (IMRT) are less apt to suffer serious gastrointestinal complications following their treatment than those who receive three-dimensional conformal radiotherapy (CRT), according to new research from the University of Pennsylvania School of Medicine.

27 Oct 2010

Endocrine disrupting chemicals may affect human reproductive system: Research

New research has provided the first evidence that 'gender bending' chemicals which find their way from human products into rivers and oceans can have a significant impact on the ability of fish to breed in UK Rivers.

27 Oct 2010